Physician profile
Nancy Chen
NPI 1063742534
$8,686.87
in general payments reported to CMS, 2019-2025
28 companies · $1,779 in 2025
The $1,779 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $943 · 2020: $21.06 · 2021: $709 · 2022: $1,533 · 2023: $1,744 · 2024: $1,958 · 2025: $1,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,405 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,404.71 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,681.00 | 2019-2024 | Xifaxan, Trulance |
| Lumenis Be INC | $981.04 | 2025 | M22 |
| Abbvie INC. | $979.71 | 2019-2025 | Rinvoq, Mavyret, Skyrizi |
| Janssen Biotech, INC. | $549.69 | 2022-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $543.75 | 2019-2024 | |
| Celgene Corporation | $541.63 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $422.87 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $409.22 | 2022-2025 | Ibsrela |
| Pfizer INC. | $397.69 | 2019-2025 | |
| Qol Medical, LLC | $380.61 | 2022-2024 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $302.86 | 2021-2024 | Linzess |
| Redhill Biopharma INC. | $284.70 | 2021-2024 | Talicia |
| Aimmune Therapeutics, INC. | $236.52 | 2024-2025 | Zenpep |
| Intra-Sana Laboratories | $179.09 | 2023-2024 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Takeda Pharmaceuticals U.S.A., INC. | $141.77 | 2019-2025 | Entyvio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $101.87 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $96.09 | 2021-2024 | Dificid |
| Vivus LLC | $88.42 | 2022 | |
| Intercept Pharmaceuticals, INC. | $64.40 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $58.86 | 2023-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $50.07 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $47.34 | 2024 | |
| Genzyme Corporation | $43.26 | 2024 | |
| Novo Nordisk INC | $28.31 | 2025 | Ozempic |
| Lilly USA, LLC | $24.20 | 2024 | Zepbound, Omvoh |
| Romark Laboratories, Lc | $18.53 | 2019 | |
| Nestle Healthcare Nutrition INC. | $17.61 | 2023 | |
| Capsovision, INC. | $15.76 | 2024 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.